TA125 Psoriatic arthritis (moderate to severe) - adalimumab: guidance
The published full technology appraisal on Psoriatic arthritis (moderate to severe) - adalimumab including recommendations and methods used.
|
TA125 Psoriatic arthritis (moderate to severe) - adalimumab: guidance
22 August 2007 (249.22 Kb 1 mins 12 sec) |
